{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:24:33Z","timestamp":1773908673415,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uveal melanoma (UM) is a rare but aggressive cancer, which is the most common primary intraocular malignancy in adults. We aimed to develop and validate a competing risk nomogram to predict cancer-specific survival (CSS) of patients with UM, as well as compare its prognostic value with that of the American Joint Committee on Cancer (AJCC) staging system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of patients diagnosed with UM from 2010 to 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. We extracted and integrated significant prognostic factors based on competing risk regression to build a nomogram. The nomogram with an online prediction version was also created. The performance of the nomogram was evaluated using Harrell\u2019s concordance index (C-index) and calibration plots. Receiver operating characteristic (ROC) curve was carried out to estimate clinical applicability of the model. Improvements in the predictive accuracy of our new model compared with AJCC staging system were estimated by calculating the relative integrated discrimination improvement (IDI) and the net reclassification improvement (NRI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 839 eligible patients with primary UM were randomly assigned to a training cohort (588, 70%) and a validation cohort (251, 30%). Age, histological type, T stage and M stage were independent prognostic factors to predict CSS of UM and were incorporated in the nomogram. The calibration plots indicated that the 3- and 5-year CSS probabilities were consistent between the nomogram prediction and the actual observation. The C-index for this model was 0.778 (95% CI:0.756\u20130.800) and 0.786 (95% CI: 0.749\u20130.816) in the training cohort and validation cohort. Areas under the curve (AUCs) were 0.814, 0.771, and 0.792 in the training cohort, 0.788, 0.781 and 0.804 in the validation cohort, respectively. The NRI value in AJCC staging system was \u2212\u20090.153 (95% CI -0.29 \u2013 \u2212\u20090.041) for 3\u2009years of follow-up and\u2009\u2212\u20090.276 (95% CI -0.415 \u2013 \u2212\u20090.132) for 5\u2009years of follow-up. The IDI values for 3 and 5\u2009years of follow-up in the AJCC staging system were\u2009\u2212\u20090.021 (<jats:italic>P<\/jats:italic>\u2009=\u20090.076) and\u2009\u2212\u20090.045 (<jats:italic>P<\/jats:italic>\u2009=\u20090.004), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We have developed and validated a competing risk nomogram to reliably predict cancer-specific survival of patients with UM. This convenient tool may be useful for evaluating cancer-specific prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-01968-6","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:02:30Z","timestamp":1621900950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Development and validation of a nomogram to predict cancer-specific survival of uveal melanoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Qiaozhu","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuou","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"issue":"9","key":"1968_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.040.","journal-title":"Ophthalmology."},{"issue":"8","key":"1968_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664\u201378. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G.","journal-title":"Cancer."},{"issue":"11","key":"1968_CR3","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651\u20139. https:\/\/doi.org\/10.1167\/iovs.03-0538.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1968_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000480640","volume":"4","author":"ME Aronow","year":"2018","unstructured":"Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013). Ocul Oncol Pathol. 2018;4(3):145\u201351. https:\/\/doi.org\/10.1159\/000480640.","journal-title":"Ocul Oncol Pathol"},{"issue":"6","key":"1968_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134. https:\/\/doi.org\/10.1245\/s10434-010-0985-4.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1968_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.5858\/133.8.1197","volume":"133","author":"PT Finger","year":"2009","unstructured":"Finger PT. 7th edition, AJCC-UICC ophthalmic oncology task force. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. Arch Pathol Lab Med. 2009;133(8):1197\u20138. https:\/\/doi.org\/10.5858\/133.8.1197.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"1968_CR7","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1245\/s10434-019-07318-7","volume":"26","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Mayne N, Yang CJ, D'Amico TA, Ng CSH, Liu CC, et al. AME thoracic surgery collaborative group. A Nomogram for predicting Cancer-specific survival of TNM 8th edition stage I non-small-cell lung Cancer. Ann Surg Oncol. 2019;26(7):2053\u201362. https:\/\/doi.org\/10.1245\/s10434-019-07318-7.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1968_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1245\/s10434-018-6929-0","volume":"26","author":"X Tang","year":"2019","unstructured":"Tang X, Zhou X, Li Y, Wang Y, Huang M, Ren L, et al. A novel Nomogram and risk classification system predicting the Cancer-specific survival of patients with initially diagnosed metastatic esophageal Cancer: a SEER-based study. Ann Surg Oncol. 2019;26(2):321\u20138. https:\/\/doi.org\/10.1245\/s10434-018-6929-0.","journal-title":"Ann Surg Oncol"},{"issue":"446","key":"1968_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Amer statist Assoc 94: 496-509. J Am Stat Assoc. 1999;94(446):496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"1968_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/biostatistics\/2.1.85","volume":"2","author":"JP Fine","year":"2001","unstructured":"Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics. 2001;2(1):85\u201397. https:\/\/doi.org\/10.1093\/biostatistics\/2.1.85.","journal-title":"Biostatistics."},{"key":"1968_CR11","volume-title":"Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Surviva l Analysis","author":"H Frank","year":"2015","unstructured":"Frank H. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression and Surviva l Analysis. New York: Springer; 2015."},{"issue":"8","key":"1968_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364\u201370. https:\/\/doi.org\/10.1200\/JCO.2007.12.9791.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1968_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/sim.2987","volume":"27","author":"NR Cook","year":"2008","unstructured":"Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., statistics in medicine. Stat Med. 2008;27(2):191\u20135. https:\/\/doi.org\/10.1002\/sim.2987.","journal-title":"Stat Med"},{"issue":"5","key":"1968_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0161-6420(03)00077-0","volume":"110","author":"AD Singh","year":"2003","unstructured":"Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):962\u20135. https:\/\/doi.org\/10.1016\/S0161-6420(03)00077-0.","journal-title":"Ophthalmology."},{"issue":"15","key":"1968_CR15","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/cncr.29727","volume":"122","author":"C Chattopadhyay","year":"2016","unstructured":"Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer. 2016;122(15):2299\u2013312. https:\/\/doi.org\/10.1002\/cncr.29727.","journal-title":"Cancer."},{"key":"1968_CR16","doi-asserted-by":"crossref","unstructured":"Xu Y, Lou L, Wang Y, Miao Q, Jin K, Chen M, et al. Epidemiological study of Uveal Melanoma from US surveillance, epidemiology, and end results program (2010-2015). J Ophthalmol. 2020:3614039.","DOI":"10.1155\/2020\/3614039"},{"key":"1968_CR17","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2147\/OPTH.S113623","volume":"10","author":"K Mahendraraj","year":"2016","unstructured":"Mahendraraj K, Lau CS, Lee I, Chamberlain RS. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the surveillance, epidemiology, and end results database (1973-2012). Clin Ophthalmol. 2016;10:2113\u20139. https:\/\/doi.org\/10.2147\/OPTH.S113623.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1968_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/02713683.2016.1245422","volume":"42","author":"H Yue","year":"2017","unstructured":"Yue H, Qian J, Yuan Y, Zhang R, Bi Y, Meng F, et al. Clinicopathological characteristics and prognosis for survival after Enucleation of Uveal melanoma in Chinese patients: long-term follow-up. Curr Eye Res. 2017;42(5):759\u201365. https:\/\/doi.org\/10.1080\/02713683.2016.1245422.","journal-title":"Curr Eye Res"},{"issue":"11","key":"1968_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/bjo.77.11.688","volume":"77","author":"K Coleman","year":"1993","unstructured":"Coleman K, Baak JP, Van Diest P, Mullaney J, Farrell M, Fenton M. Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol. 1993;77(11):688\u201392. https:\/\/doi.org\/10.1136\/bjo.77.11.688.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1968_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/archopht.126.10.1413","volume":"126","author":"G Virgili","year":"2008","unstructured":"Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Paci E; EUROCARE working group. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol. 2008;126(10):1413\u20138. https:\/\/doi.org\/10.1001\/archopht.126.10.1413.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1968_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09286580600977281","volume":"14","author":"JM Burr","year":"2007","unstructured":"Burr JM, Mitry E, Rachet B, Coleman MP. Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol. 2007;14(1):3\u20138. https:\/\/doi.org\/10.1080\/09286580600977281.","journal-title":"Ophthalmic Epidemiol"},{"issue":"8","key":"1968_CR22","first-page":"2579","volume":"43","author":"L Bergman","year":"2002","unstructured":"Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2002;43(8):2579\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"1968_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/09286580600553330","volume":"13","author":"P Isager","year":"2006","unstructured":"Isager P, Engholm G, Overgaard J, Storm H. Uveal and conjunctival malignant melanoma in Denmark 1943-97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol. 2006;13(2):85\u201396. https:\/\/doi.org\/10.1080\/09286580600553330.","journal-title":"Ophthalmic Epidemiol"},{"issue":"7","key":"1968_CR24","first-page":"1230","volume":"6","author":"P Jovanovic","year":"2013","unstructured":"Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6(7):1230\u201344.","journal-title":"Int J Clin Exp Pathol"},{"key":"1968_CR25","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","volume":"75","author":"KN Smit","year":"2020","unstructured":"Smit KN, Jager MJ, de Klein A, Kili\u04ab E. Uveal melanoma: towards a molecular understanding. Prog Retin Eye Res. 2020;75:100800. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.100800.","journal-title":"Prog Retin Eye Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01968-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-01968-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01968-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:02:44Z","timestamp":1621900964000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-01968-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-01968-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}